Sun Pharmaceutical industries share price has declined 4-5% in 2 trading sessions following OAI status determined by the ...
Stagnant liquid inside an air purification unit, hundreds of complaints on tablet counts and inadequate guidance to call centers are but a few of the litany of issues outlined in the FDA’s Form 483 ...
Sun Pharma said that the US FDA conducted an inspection at the company's Dadra facility from December 4, 2023 to December 15, 2023. The US FDA has subsequently determined the inspection ...
Sun Pharmaceutical Industries shares dropped 3.4 percent as the US FDA labelled its Dadra facility ... taking any investment decisions. Advisory Alert: It has come to our attention that certain ...
On 18 April, Mumbai-headquartered Marksans Pharma, a drugmaker that supplies generic drugs in over 50 countries around the ...
Dadra's specialization lies in the production of oral solid dosage forms and the manufacture of the blockbuster drug Revlimid, a vital revenue driver for Sun ... Advisory Alert: It has come ...
The agency increased the blockade because Jiangsu Shenli Medical Production failed to meet device quality system requirements.
The FDA said U.S. healthcare workers should avoid all plastic syringes manufactured by Jiangsu Shenli Medical Production as the agency investigates multiple syringe suppliers. In two import alerts ...
[Related: Taro announces merger agreement with Sun Pharma] At the meetings, Taro shareholders will be asked to consider and vote on the approval, pursuant to Section 320 of the Companies Law ...
A stock is considered to be oversold if the RSI reading falls below 30. In trading on Friday, shares of Royalty Pharma plc (Symbol: RPRX) entered into oversold territory, hitting an RSI reading of ...
The Sun Pharma's ordeal with the US drug regulator continues as its Halol Manufacturing facility in Gujarat is already under USFDA scanner facing import alert. Its Mohali unit also swaits USFDA ...